US4650764A
(en)
|
1983-04-12 |
1987-03-17 |
Wisconsin Alumni Research Foundation |
Helper cell
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
US4844893A
(en)
|
1986-10-07 |
1989-07-04 |
Scripps Clinic And Research Foundation |
EX vivo effector cell activation for target cell killing
|
US4980289A
(en)
|
1987-04-27 |
1990-12-25 |
Wisconsin Alumni Research Foundation |
Promoter deficient retroviral vector
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US5124263A
(en)
|
1989-01-12 |
1992-06-23 |
Wisconsin Alumni Research Foundation |
Recombination resistant retroviral helper cell and products produced thereby
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
ATE145428T1
(de)
|
1990-12-14 |
1996-12-15 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
US5674704A
(en)
|
1993-05-07 |
1997-10-07 |
Immunex Corporation |
Cytokine designated 4-IBB ligand
|
US5653977A
(en)
|
1993-09-09 |
1997-08-05 |
Uab Research Foundation |
Anti-idiotypic antibody that mimics the GD2 antigen
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
US20020018783A1
(en)
|
1997-03-20 |
2002-02-14 |
Michel Sadelain |
Fusion proteins of a single chain antibody and cd28 and uses thereof
|
GB9725764D0
(en)
|
1997-12-04 |
1998-02-04 |
Isis Innovation |
HLA-E binding
|
AU741602B2
(en)
|
1998-02-02 |
2001-12-06 |
Johns Hopkins University School Of Medicine, The |
A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
|
EP1104455A2
(de)
|
1998-06-25 |
2001-06-06 |
Hemosol Inc. |
Verfahren und kulturmedien zur vermehrung von erythroide vorläuferzellen zur produktion von hämoglobin
|
WO2000023573A2
(en)
|
1998-10-20 |
2000-04-27 |
City Of Hope |
Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
|
EP1171596A1
(de)
|
1999-04-16 |
2002-01-16 |
Celltech Therapeutics Limited |
Synthetische transmembrankomponenten
|
JP3619853B2
(ja)
|
1999-11-26 |
2005-02-16 |
独立行政法人理化学研究所 |
ナチュラルキラー細胞の増殖方法
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
WO2002077029A2
(en)
|
2000-11-07 |
2002-10-03 |
City Of Hope |
Cd19-specific redirected immune cells
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
DE60232083D1
(de)
|
2001-08-15 |
2009-06-04 |
Takara Bio Inc |
Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten
|
CA2457143A1
(en)
|
2001-08-17 |
2003-02-27 |
Roger Williams Hospital |
In situ immunization
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
WO2003089616A2
(en)
|
2002-04-22 |
2003-10-30 |
Fred Hutchinson Cancer Research Center |
Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
US7740871B2
(en)
|
2002-09-19 |
2010-06-22 |
Johns Hopkins University School Of Medicine |
Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
|
GB0225279D0
(en)
|
2002-10-30 |
2002-12-11 |
Celltech R&D Ltd |
Biological products
|
US9068234B2
(en)
|
2003-01-21 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating gene expression
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
CA2530349A1
(en)
|
2003-06-27 |
2005-01-06 |
Dnavec Research Inc. |
Method for transplanting lymphohematopoietic cells into mammal
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
EP1765988B1
(de)
*
|
2004-05-27 |
2017-09-20 |
The Trustees of The University of Pennsylvania |
Neue künstliches antigen präsentierende zellen und verwendungen dafür
|
ATE443084T1
(de)
|
2004-07-10 |
2009-10-15 |
Fox Chase Cancer Ct |
Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
|
WO2006036445A2
(en)
|
2004-09-24 |
2006-04-06 |
Trustees Of Dartmouth College |
Chimeric nk receptor and methods for treating cancer
|
GB0426903D0
(en)
|
2004-12-08 |
2005-01-12 |
Alexis Biotech Ltd |
Complexes and methods
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
EP1777294A1
(de)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi Domäin als selektieve und potente Enhancer von IL-15 Aktion durch IL-15Rbeta/gamma, und Hyperagonist (IL15Ralpha sushi -IL15) Fusionsproteine
|
US20070160578A1
(en)
|
2005-12-14 |
2007-07-12 |
The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services |
Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
|
US7932055B2
(en)
|
2006-06-22 |
2011-04-26 |
Novo Nordisk A/S |
Soluble heterodimeric CD94/NKG2 receptors fusion proteins
|
EP2141997B1
(de)
|
2007-03-30 |
2012-10-31 |
Memorial Sloan-Kettering Cancer Center |
Konstitutive expression kostimulierender liganden auf adoptiv transferierten t-lymphozyten
|
WO2009117566A1
(en)
|
2008-03-21 |
2009-09-24 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Chemokine gene-modified cells for cancer immunotherapy
|
CA2735456C
(en)
|
2008-08-26 |
2021-11-16 |
City Of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
CN101684456A
(zh)
*
|
2008-09-28 |
2010-03-31 |
江门罗森生物制药有限公司 |
一种体外培养条件下扩增人nk细胞的方法
|
WO2010071836A1
(en)
|
2008-12-19 |
2010-06-24 |
Inserm |
Il-15 mediated nk and t cell maturation
|
CN102428173B
(zh)
|
2009-03-26 |
2014-07-30 |
细胞维护北欧制药公司 |
Nk细胞的扩增
|
EP3135294B1
(de)
|
2009-08-14 |
2020-06-03 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Verwendung von il-15 zur erhöhung der thymusleistung und zur behandlung von lymphopenie
|
US20130058921A1
(en)
|
2009-10-30 |
2013-03-07 |
Frits VAN RHEE |
Use of autologous effector cells and antibodies for treatment of multiple myeloma
|
EP2493485A1
(de)
|
2009-10-30 |
2012-09-05 |
University Of Arkansas For Medical Science |
Verwendung von autologen effektorzellen zur behandlung von multiplem myelom
|
MX354143B
(es)
|
2009-12-02 |
2018-02-14 |
Imaginab Inc |
Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
|
EP3184109B1
(de)
|
2009-12-29 |
2020-11-18 |
Gamida-Cell Ltd. |
Methoden zur verstärkung des wachstums und der aktivierung von nk-zellen
|
US9422598B2
(en)
|
2010-06-04 |
2016-08-23 |
Biomerieux |
Method and kit for the prognosis of colorectal cancer
|
KR20230096132A
(ko)
|
2010-07-13 |
2023-06-29 |
셀룰래리티 인코포레이티드 |
천연 킬러 세포의 생성 방법
|
EP2407531A1
(de)
|
2010-07-16 |
2012-01-18 |
Neste Oil Oyj |
Mikroorganismen mit erweitertem Substratnutzungsbereich
|
ES2754394T3
(es)
|
2010-09-08 |
2020-04-17 |
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus |
Receptores de antígenos quiméricos con una región bisagra optimizada
|
US9487800B2
(en)
|
2010-09-08 |
2016-11-08 |
Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus |
Interleukin 15 as selectable marker for gene transfer in lymphocytes
|
DK3327040T3
(da)
|
2010-09-21 |
2021-09-20 |
Altor Bioscience Corp |
Multimeriske opløselige il-15-fusionsmolekyler og fremgangsmåder til at fremstille og anvende samme
|
CN106963947A
(zh)
|
2010-11-22 |
2017-07-21 |
伊纳特医药股份有限公司 |
Nk细胞调节治疗和用于治疗血液恶性疾病的方法
|
EP3305798A1
(de)
|
2010-12-09 |
2018-04-11 |
The Trustees of The University of Pennsylvania |
Verwendung von durch einen chimären antigenrezeptor modifizierten t-zellen zur behandlung von krebs
|
US20120321666A1
(en)
|
2011-05-23 |
2012-12-20 |
Cooper Laurence J N |
T cell therapy for b cell lymphoma
|
KR20140060541A
(ko)
|
2011-09-16 |
2014-05-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 rna 조작된 t 세포
|
US20140255363A1
(en)
|
2011-09-16 |
2014-09-11 |
Baylor College Of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
BR112014007029A2
(pt)
|
2011-09-23 |
2017-04-11 |
Bluebird Bio Inc |
métodos aperfeiçoados de terapia gênica
|
ITMO20110270A1
(it)
|
2011-10-25 |
2013-04-26 |
Sara Caldrer |
Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
|
CN103294374A
(zh)
|
2012-02-23 |
2013-09-11 |
中兴通讯股份有限公司 |
一种触摸屏解锁方法及装置
|
CN104750498B
(zh)
|
2012-02-24 |
2018-12-18 |
青岛海信电器股份有限公司 |
一种控制鼠标模块的方法及电子设备
|
PT3578201T
(pt)
|
2012-06-28 |
2023-05-10 |
Univ Of Central Florida Research Foundation Incorporated |
Métodos e composições para células assassinas naturais
|
US20160235787A1
(en)
|
2012-07-13 |
2016-08-18 |
The Trustees Of The University Of Pennsylvania |
Epitope Spreading Associated with CAR T-Cells
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
CA2918608A1
(en)
|
2012-08-03 |
2014-02-06 |
Icahn School Of Medicine At Mount Sinai |
Biomarker associated with risk of melanoma reoccurrence
|
US9365641B2
(en)
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
WO2014055413A2
(en)
|
2012-10-02 |
2014-04-10 |
Bloodcenter Research Foundation |
A method of providing cellular therapy using modified natural killer cells or t lymphocytes
|
CN112430580A
(zh)
|
2012-10-02 |
2021-03-02 |
纪念斯隆-凯特琳癌症中心 |
用于免疫疗法的组合物和方法
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
US20150329640A1
(en)
|
2012-12-20 |
2015-11-19 |
Bluebird Bio, Inc. |
Chimeric antigen receptors and immune cells targeting b cell malignancies
|
US9511092B2
(en)
|
2013-01-28 |
2016-12-06 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
|
CN105142677B
(zh)
|
2013-02-15 |
2019-08-30 |
加利福尼亚大学董事会 |
嵌合抗原受体及其使用方法
|
KR20210108497A
(ko)
|
2013-02-26 |
2021-09-02 |
메모리얼 슬로안 케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
CN103113470B
(zh)
|
2013-02-27 |
2015-04-22 |
四川大学 |
靶向人egfr的基因工程化淋巴细胞及其制备方法和用途
|
CA2904369A1
(en)
|
2013-03-07 |
2014-09-12 |
Baylor College Of Medicine |
Targeting cd138 in cancer
|
US20160024175A1
(en)
|
2013-03-10 |
2016-01-28 |
Baylor College Of Medicine |
Chemotherapy-resistant immune cells
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
KR20150128997A
(ko)
|
2013-03-15 |
2015-11-18 |
메모리얼 슬로안-케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
EP2986636B1
(de)
|
2013-04-17 |
2018-11-14 |
Baylor College Of Medicine |
Immunosuppressive tgf-beta signalwandler
|
EP3783098A1
(de)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Menschliche anwendung manipulierter chimärer antigen-rezeptor (car)-t-zellen
|
CA2912389C
(en)
|
2013-06-10 |
2020-01-28 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for reducing immunosupression by tumor cells
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
CA2926267C
(en)
|
2013-10-17 |
2023-08-01 |
National University Of Singapore |
Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
|
CN105873952A
(zh)
|
2013-10-31 |
2016-08-17 |
弗莱德哈钦森癌症研究中心 |
经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
|
PT3071222T
(pt)
|
2013-11-21 |
2020-11-20 |
Ucl Business Plc |
Célula
|
BR112016014156A8
(pt)
|
2013-12-20 |
2023-04-11 |
Hutchinson Fred Cancer Res |
Moléculas efetoras quiméricas etiquetadas e receptores das mesmas
|
EP3808410A1
(de)
|
2013-12-20 |
2021-04-21 |
Cellectis |
Verfahren zur manipulation von für mehrere eingangssignale empfindlichen t-zellen zur immuntherapie
|
EP3094653B1
(de)
|
2014-01-13 |
2019-10-23 |
Stephen J. Forman |
Chimäre antigenrezeptoren (cars) mit mutationen in der fc-spacerregion und verfahren zu deren verwendung
|
US20170015975A1
(en)
|
2014-02-10 |
2017-01-19 |
Nvigen, Inc. |
Cell modulation nanocomposition, and methods of use
|
KR102375998B1
(ko)
|
2014-02-14 |
2022-03-21 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
키메라 항원 수용체 및 제조방법
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
GB201405845D0
(en)
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
WO2015154012A1
(en)
|
2014-04-03 |
2015-10-08 |
Memorial Sloan-Kettering Cancer Center |
Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
|
CN110938655A
(zh)
|
2014-04-25 |
2020-03-31 |
蓝鸟生物公司 |
Mnd启动子嵌合抗原受体
|
SG11201609118RA
(en)
|
2014-05-15 |
2016-11-29 |
Univ Singapore |
Modified natural killer cells and uses thereof
|
ES2846811T3
(es)
|
2014-06-06 |
2021-07-29 |
Bluebird Bio Inc |
Composiciones de células T mejoradas
|
US10550197B2
(en)
|
2014-06-18 |
2020-02-04 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
CAR-expressing NK-92 cells as cell therapeutic agents
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
EP3180359A1
(de)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Behandlung von krebs mit einem chimären gfr-alpha-4-antigenrezeptor
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
EP4074735A1
(de)
|
2014-08-28 |
2022-10-19 |
BioAtla, Inc. |
Bedingt aktive chimäre antigenrezeptoren für modifizierte t-zellen
|
GB201415347D0
(en)
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
CA2996848C
(en)
|
2014-09-04 |
2021-01-05 |
Stemcell Technologies Inc. |
Soluble antibody complexes for t cell or nk cell activation and expansion
|
EP3191507A1
(de)
|
2014-09-09 |
2017-07-19 |
Unum Therapeutics |
Chimäre rezeptoren und verwendungen in der immuntherapie
|
RU2745705C2
(ru)
|
2014-09-15 |
2021-03-30 |
МОЛМЕД СпА |
Химерные рецепторы антигенов
|
US20170246217A1
(en)
|
2014-09-16 |
2017-08-31 |
Funndación Pública Andaluza Progreso y Salud |
Use of cord blood plasma to treat nk cell-mediated diseases and ifn-γ mediated diseases
|
MA41538A
(fr)
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
WO2016069607A1
(en)
|
2014-10-27 |
2016-05-06 |
University Of Central Florida Research Foundation, Inc. |
Methods and compositions for natural killer cells
|
NZ769595A
(en)
|
2014-11-05 |
2023-06-30 |
Juno Therapeutics Inc |
Methods for transduction and cell processing
|
JP2017535284A
(ja)
|
2014-11-05 |
2017-11-30 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
|
EP3215534B1
(de)
|
2014-11-05 |
2020-04-15 |
Board of Regents, The University of Texas System |
Chimäre antigenrezeptoren (car) zur selektiven abzielung auf proteinkomplexe
|
EP3018200A1
(de)
|
2014-11-07 |
2016-05-11 |
Fondazione Matilde Tettamanti e Menotti de Machi Onlus |
Verbessertes Verfahren zur Erzeugung von genetisch veränderten Zellen
|
CA2967222C
(en)
|
2014-11-12 |
2023-10-31 |
Rinat Neuroscience Corp. |
Inhibitory chimeric antigen receptors
|
IL252295B2
(en)
|
2014-12-19 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
Chimeric antigen receptors and methods of using them
|
WO2016109661A1
(en)
|
2014-12-31 |
2016-07-07 |
Anthrogenesis Corporation |
Natural killer cells and uses thereof
|
JP6797803B2
(ja)
|
2014-12-31 |
2020-12-09 |
セルジーン コーポレイション |
ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
US10377988B2
(en)
|
2015-01-23 |
2019-08-13 |
Musc Foundation For Research Development |
Cytokine receptor genes and the use thereof to enhance therapy
|
MA41433A
(fr)
|
2015-01-26 |
2017-12-05 |
Baylor College Medicine |
Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
|
EP3250587B1
(de)
|
2015-01-29 |
2020-03-25 |
Regents of the University of Minnesota |
Chimäre antigenrezeptoren, zusammensetzungen und verfahren
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
GB201501936D0
(en)
|
2015-02-05 |
2015-03-25 |
Ucl Business Plc |
Signalling system
|
AU2016214301B2
(en)
|
2015-02-06 |
2022-05-19 |
Cellectis |
Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
|
US10765699B2
(en)
|
2015-02-06 |
2020-09-08 |
National University Of Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
EP3265481B1
(de)
|
2015-03-05 |
2024-05-01 |
Fred Hutchinson Cancer Center |
Immunomodulatorische fusionsproteine und verwendungen davon
|
GB201503742D0
(en)
|
2015-03-05 |
2015-04-22 |
Ucl Business Plc |
Chimeric antigen receptor
|
EP3064507A1
(de)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusionsproteine mit einem bindenden Protein und einem Interleukin-15-Polypeptid mit reduzierter Affinität für IL15ra und therapeutische Verwendungen davon
|
US9777064B2
(en)
|
2015-03-17 |
2017-10-03 |
Chimera Bioengineering, Inc. |
Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof
|
CN107614008A
(zh)
|
2015-03-20 |
2018-01-19 |
蓝鸟生物公司 |
载体制剂
|
GB201504840D0
(en)
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
WO2016154585A1
(en)
|
2015-03-26 |
2016-09-29 |
Charles Sentman |
Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
|
CN108367057B
(zh)
|
2015-04-06 |
2022-11-22 |
赛通免疫股份有限公司 |
用于胶质母细胞瘤的egfr导向的car疗法
|
US20180092968A1
(en)
|
2015-04-23 |
2018-04-05 |
The Trustees Of The University Of Pennsylvania |
Compositions to disrupt protein kinase a anchoring and uses thereof
|
EP3286211A1
(de)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker
|
GB201507119D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
GB201507115D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
GB201507108D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
GB201507104D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
GB201507111D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
GB201507368D0
(en)
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
CA3021226A1
(en)
*
|
2015-05-11 |
2016-11-17 |
University Health Network |
Method for expansion of double negative regulatory t cells
|
AU2016268863B2
(en)
|
2015-05-28 |
2022-06-23 |
Kite Pharma, Inc. |
Diagnostic methods for T cell therapy
|
EP3302547A1
(de)
|
2015-05-28 |
2018-04-11 |
Armo Biosciences, Inc. |
Pegyliertes interleukin-10 zur behandlung von krebs
|
EP3303586A1
(de)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics, Inc. |
Zusammensetzung und verfahren zur regulierung von inhibitorischen wechselwirkungen in gentechnisch veränderten zellen
|
US11154572B2
(en)
|
2015-06-05 |
2021-10-26 |
Board Of Regents, The University Of Texas System |
Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
|
AU2016275030B2
(en)
|
2015-06-10 |
2021-12-09 |
Nantkwest, Inc. |
Modified NK-92 cells for treating cancer
|
JP6556523B2
(ja)
|
2015-06-24 |
2019-08-07 |
株式会社やまびこ |
層状掃気式2サイクル内燃エンジン用のエアクリーナ
|
US11655452B2
(en)
|
2015-06-25 |
2023-05-23 |
Icell Gene Therapeutics Inc. |
Chimeric antigen receptors (CARs), compositions and methods of use thereof
|
AU2016285859A1
(en)
|
2015-06-29 |
2018-02-15 |
The Johns Hopkins University |
Immune checkpoint chimeric antigen receptors therapy
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
WO2017023859A1
(en)
|
2015-07-31 |
2017-02-09 |
Memorial Sloan-Kettering Cancer Center |
Antigen-binding proteins targeting cd56 and uses thereof
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
CA2993354A1
(en)
|
2015-08-04 |
2017-02-09 |
Avidbiotics Corp. |
Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors
|
KR20180050321A
(ko)
|
2015-08-07 |
2018-05-14 |
이미지냅 인코포레이티드 |
분자를 표적화하기 위한 항원 결합 구조체
|
GB201514874D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
BR112018002189A2
(pt)
|
2015-08-24 |
2018-09-18 |
Cellectis |
receptores antigênicos quiméricos com funções controláveis integradas
|
EP3138905A1
(de)
|
2015-09-04 |
2017-03-08 |
Miltenyi Biotec GmbH |
Verfahren für natürliche killerzellenexpansion
|
WO2017058752A1
(en)
|
2015-09-28 |
2017-04-06 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
US20180291080A1
(en)
|
2015-09-28 |
2018-10-11 |
Trustees Of Dartmouth College |
Chimeric antigen receptor, regulatory cells and methods of use
|
JP6932709B2
(ja)
|
2015-11-04 |
2021-09-08 |
ジェイ. プライスマン,ソール |
Her2を標的とするキメラ抗原受容体
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
CN107109363A
(zh)
|
2015-11-09 |
2017-08-29 |
张明杰 |
增强对异常细胞杀伤力的方法和药物组合物
|
EP3383892B1
(de)
|
2015-12-03 |
2022-12-21 |
Juno Therapeutics, Inc. |
Modifizierte chimärische rezeptoren und entsprechende zusammensetzungen und verfahren
|
JP6853514B2
(ja)
|
2015-12-27 |
2021-03-31 |
国立大学法人東海国立大学機構 |
炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球
|
CA3010236A1
(en)
|
2016-01-20 |
2017-07-27 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
US20190112380A1
(en)
|
2016-03-29 |
2019-04-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
CN110358736B
(zh)
|
2016-05-20 |
2023-07-07 |
杭州朔溪生物医药有限公司 |
一种修饰的k562细胞、其制备方法及nk细胞培养组合物
|
AU2017279548A1
(en)
|
2016-06-08 |
2018-12-13 |
Precigen, Inc. |
Cd33 specific chimeric antigen receptors
|
CN105985931A
(zh)
|
2016-06-21 |
2016-10-05 |
黑龙江天晴干细胞股份有限公司 |
一种nk细胞体外扩增组合物及nk细胞扩增方法
|
CA2937157A1
(en)
|
2016-07-25 |
2018-01-25 |
Ucl Business Plc |
Protein-based t-cell receptor knockdown
|
EP3487991B1
(de)
|
2016-07-25 |
2022-09-07 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Verfahren zur herstellung von modifizierten natürlichen killerzellen und verfahren zur verwendung
|
MX2019006438A
(es)
|
2016-12-05 |
2019-11-28 |
Juno Therapeutics Inc |
Produccion de celulas modificadas para terapia de celulas adoptivas.
|
CN108148862B
(zh)
|
2016-12-05 |
2019-03-08 |
上海优卡迪生物医药科技有限公司 |
一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
|
CA3061898A1
(en)
|
2016-12-28 |
2019-10-29 |
Green Cross Lab Cell Corporation |
Chimeric antigen receptor and natural killer cells expressing same
|
US20230002471A1
(en)
|
2017-03-27 |
2023-01-05 |
National University Of Singapore |
Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
|
EP3600356A4
(de)
|
2017-03-27 |
2020-12-23 |
National University of Singapore |
Verkürzte chimäre nkg2d-rezeptoren und verwendungen davon in der immuntherapie mit natürlichen killerzellen
|
WO2018182511A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
EP3665270A4
(de)
|
2017-08-10 |
2021-04-21 |
National University of Singapore |
T-zell-rezeptor-defiziente chimäre antigen-rezeptor-t-zellen und verfahren zu ihrer verwendung
|
CN109554348A
(zh)
|
2017-09-27 |
2019-04-02 |
亘喜生物科技(上海)有限公司 |
可诱导分泌抗cd47抗体的工程化免疫细胞
|
US20210128615A1
(en)
|
2017-10-18 |
2021-05-06 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Methods and compounds for improved immune cell therapy
|
CN107827990B
(zh)
|
2017-10-30 |
2020-07-10 |
河北森朗生物科技有限公司 |
一种多肽、编码其的核酸、其修饰的t淋巴细胞及其应用
|
CN109971712B
(zh)
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
|
WO2019127215A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
|
CA3089167A1
(en)
|
2018-02-09 |
2019-08-15 |
National University Of Singapore |
Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy
|
US20210046115A1
(en)
|
2018-02-09 |
2021-02-18 |
National University Of Singapore |
Activating Chimeric Receptors and Uses Thereof In Natural Killer Cell Immunotherapy
|
CA3093518A1
(en)
|
2018-04-02 |
2019-10-10 |
National University Of Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
WO2020044239A1
(en)
|
2018-08-29 |
2020-03-05 |
National University Of Singapore |
A method to specifically stimulate survival and expansion of genetically-modified immune cells
|
CN111088231A
(zh)
|
2018-10-24 |
2020-05-01 |
艾生命序公司 |
Pd-l1抗体分泌的抗间皮素car-t细胞肿瘤免疫治疗
|
CN114286683A
(zh)
|
2019-07-17 |
2022-04-05 |
新加坡国立大学 |
由免疫细胞合成和分泌的功能性结合物
|